Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections
Avi Hasson, Chief Scientist of Israel’s Ministry of Economy, said at the award ceremony: ”Qlight Nanotech encompasses a winning combination of outstanding technology originating from the Hebrew University together with a leading international...
Novel sodium-ion battery is an environmentally friendly, economic and efficient solution for a variety of applications including electric vehicles and stationary storage for renewable energies
Yissum presents new oxidation-resistant copper nano-inks with a low sintering temperature (lower than 150oC), which enables the printing of low-cost conductive patterns on heat sensitive plastic substrates. Due to these traits, the new inks,...
The technology uses certain bacteria as novel bio-filters to reduce nitrate levels in both fresh-water and sea-water aquariums.
The novel polymer-clay composites have a higher pollutant removal capacity in comparison to activated carbon (the most common sorbent). The technology will be presented at the WATEC Conference, to be held in Tel Aviv, Israel on October 22-24, 2013.
The announcement was made at the opening of the new site of Qlight at the Edmond J. Safra Givat Ram Campus of the Hebrew University of Jerusalem in the presence of a senior management delegation from Merck headed by Dr. Bernd Reckmann, Member of...
The invention is based on a machine-learning algorithm that predicts the next outgoing call.
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants.
A novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy. Diabetic retinopathy is a leading cause of blindness worldwide. The novel method will enable early diagnosis and...
In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim analysis is expected in H1 2014